Publicaciones (503) Publicaciones de JAVIER CORTES CASTAN

2024

  1. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

    The Lancet

  2. A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative)

    Future oncology (London, England), Vol. 20, Núm. 11, pp. 635-651

  3. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

    Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 987-993

  4. Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis

    ESMO Open, Vol. 9, Núm. 3

  5. Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial

    European Journal of Nuclear Medicine and Molecular Imaging

  6. Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab

    Breast Cancer Research and Treatment

  7. Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis

    European Journal of Cancer, Vol. 202

  8. Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)

    Radiotherapy and Oncology

  9. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

    Annals of Oncology

  10. Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research

    Clinical Cancer Research, Vol. 30, Núm. 6, pp. 1093-1103

  11. International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations

    The Lancet Oncology, Vol. 25, Núm. 2, pp. e73-e83

  12. Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

    eClinicalMedicine, Vol. 71

  13. Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)

    ESMO Open, Vol. 9, Núm. 3

  14. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

    Annals of Oncology, Vol. 35, Núm. 1, pp. 66-76

  15. Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis

    Frontiers in Immunology, Vol. 15

  16. The evolving value assessment of cancer therapies: Results from a modified Delphi study

    Health Policy OPEN, Vol. 6

  17. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer: a plain language summary of the DESTINY-Breast03 study

    Future oncology (London, England), Vol. 20, Núm. 4, pp. 167-178

2023

  1. A single-arm study design with non-inferiority and superiority time-to-event endpoints: a tool for proof-of-concept and de-intensification strategies in breast cancer

    Frontiers in Oncology, Vol. 13

  2. Analysis of tumor infiltrating CD4+ and CD8+ CDR3 sequences reveals shared features putatively associated to the anti-tumor immune response

    Frontiers in Immunology, Vol. 14

  3. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer

    Annals of Oncology, Vol. 34, Núm. 9, pp. 783-795